HOOKIPA Pharma (HOOK)
(Delayed Data from NSDQ)
$4.56 USD
-0.18 (-3.80%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $4.30 -0.26 (-5.70%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for HOOKIPA Pharma Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 117 | 113 | 66 | 143 | 113 |
Receivables | 19 | 22 | 21 | 21 | 10 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 11 | 12 | 14 | 8 | 5 |
Total Current Assets | 147 | 147 | 102 | 172 | 128 |
Net Property & Equipment | 8 | 18 | 16 | 6 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 2 | 2 | 1 |
Total Assets | 161 | 170 | 126 | 188 | 144 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 13 | 5 | 9 | 8 | 1 |
Current Portion Long-Term Debt | 1 | 2 | 3 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 11 | 9 | 7 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 15 | 16 | 6 | 4 | 4 |
Total Current Liabilities | 42 | 36 | 28 | 21 | 15 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 20 | 26 | 0 | 1 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 1 | 2 | 5 | 4 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6 | 3 | 3 | 1 | 2 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 71 | 68 | 36 | 32 | 26 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 467 | 397 | 317 | 309 | 226 |
Retained Earnings | -369 | -288 | -223 | -147 | -103 |
Other Equity | -8 | -7 | -5 | -6 | -5 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 90 | 103 | 90 | 156 | 118 |
Total Liabilities & Shareholder's Equity | 161 | 170 | 126 | 188 | 144 |
Total Common Equity | 90 | 103 | 90 | 156 | 118 |
Shares Outstanding | 9.90 | 5.40 | 3.10 | 2.10 | 2.10 |
Book Value Per Share | 9.08 | 18.99 | 28.90 | 74.34 | 56.14 |
Fiscal Year End for HOOKIPA Pharma Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 77 | 93 | 117 | 108 | 136 |
Receivables | 23 | 31 | 19 | 23 | 20 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 8 | 9 | 11 | 9 | 12 |
Total Current Assets | 107 | 133 | 147 | 139 | 168 |
Net Property & Equipment | 7 | 7 | 8 | 20 | 18 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 6 | 1 | 1 | 2 | 1 |
Total Assets | 125 | 146 | 161 | 164 | 191 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 11 | 13 | 9 | 12 |
Current Portion Long-Term Debt | 0 | 1 | 1 | 1 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 11 | 11 | 12 | 13 | 12 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 5 | 15 | 16 | 20 |
Total Current Liabilities | 28 | 30 | 42 | 41 | 46 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 3 | 20 | 24 | 27 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6 | 6 | 3 | 3 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 39 | 41 | 71 | 69 | 79 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 467 | 467 | 467 | 446 | 445 |
Retained Earnings | -374 | -355 | -369 | -344 | -325 |
Other Equity | -7 | -7 | -8 | -6 | -7 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 86 | 105 | 90 | 95 | 112 |
Total Liabilities & Shareholder's Equity | 125 | 146 | 161 | 164 | 191 |
Total Common Equity | 86 | 105 | 90 | 95 | 112 |
Shares Outstanding | 12.00 | 9.90 | 9.90 | 8.40 | 8.40 |
Book Value Per Share | 7.17 | 10.56 | 9.08 | 11.32 | 13.37 |